$KRRO SEC Filings

Bought 52,175 shares ($559K) · Bought 2,510 shares ($30.4K) · Bought 25,124 shares ($295K)

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background

Sold 10,200 shares ($143K) · Sold 38,490 shares ($543K)

Sold 5 shares ($68.6)

Sold 7,347 shares ($99.3K) · Sold 6 shares ($81.6)

Sold 300 shares ($4.19K)

Sold 28,468 shares ($399K)